Endometrial Cancer


Latest News

Endometrial Cancer
Patients With Endometrial Cancer Report Maintained HRQOL With Dostarlimab

November 21st 2023

Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.

endometrial cancer
Frontline Atezolizumab/Chemo Shows PFS Benefit in Advanced/Recurrent Endometrial Cancer

October 27th 2023

gynecological cancer
Durvalumab/Chemo Maintenance Followed by Olaparib Confers PFS Advantage in Endometrial Cancer

October 22nd 2023

FDA Approves Frontline Dostarlimab in Combination With Chemotherapy for dMMR/MSI-H Endometrial Cancer

July 31st 2023

gynecologic cancer
Selinexor Maintenance Demonstrates Efficacy in TP53 Wild-Type Advanced Endometrial Cancer Following Frontline Chemotherapy

July 28th 2023

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.